Primary central nervous system (CNS) lymphoma (PCNSL) is an aggressive form of non-Hodgkin lymphoma primarily involving the brain, spinal cord, leptomeninges, eyes, or cranial nerves. PCNSL accounts for approximately 2% of all primary central nervous system tumors with a median age of 65 years at diagnosis. The existence of the blood-brain barrier (BBB) is a major factor in the suboptimal delivery of chemotherapeutic drugs into the CNS, resulting in poorer outcomes for patients with PCNSL compared to those with non-CNS lymphomas.
Extensive international cooperation has allowed for the rapid development of novel therapies in this field. Methotrexate-based induction chemotherapy followed by consolidative chemotherapy or high-dose therapy and autologous stem cell transplantation has resulted in improved patient outcomes and reduced neurotoxicity. More recently, the advent of Bruton’s tyrosine kinase inhibitors and chimeric antigen receptor T-cell therapy has increased the number of treatment options available for some patients. Despite these advances, the treatment of this disease remains a challenge, with high rates of relapse and 5-year survival being reported at roughly 30%. Furthermore, as we continue to develop novel strategies for this disease, it will become increasingly important to develop minimally invasive biomarkers.
This Research Topic will focus on recent advancements in the treatment of PCNSL with the aim of improving the prognosis for patients. We welcome submissions focusing on, but not limited to, the following topics:
- Novel targeted agents for the treatment of PCNSL
- Immunomodulatory drugs for the treatment of PCNSL
- Combination therapies for the treatment of PCNSL
- Overcoming the BBB in the treatment of PCNSL
- Overcoming drug resistance in PCNSL
- Validated biomarkers for treatment response in PCNSL
Please note: manuscripts that are solely based on bioinformatics or computational analysis of public databases without validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Primary central nervous system (CNS) lymphoma (PCNSL) is an aggressive form of non-Hodgkin lymphoma primarily involving the brain, spinal cord, leptomeninges, eyes, or cranial nerves. PCNSL accounts for approximately 2% of all primary central nervous system tumors with a median age of 65 years at diagnosis. The existence of the blood-brain barrier (BBB) is a major factor in the suboptimal delivery of chemotherapeutic drugs into the CNS, resulting in poorer outcomes for patients with PCNSL compared to those with non-CNS lymphomas.
Extensive international cooperation has allowed for the rapid development of novel therapies in this field. Methotrexate-based induction chemotherapy followed by consolidative chemotherapy or high-dose therapy and autologous stem cell transplantation has resulted in improved patient outcomes and reduced neurotoxicity. More recently, the advent of Bruton’s tyrosine kinase inhibitors and chimeric antigen receptor T-cell therapy has increased the number of treatment options available for some patients. Despite these advances, the treatment of this disease remains a challenge, with high rates of relapse and 5-year survival being reported at roughly 30%. Furthermore, as we continue to develop novel strategies for this disease, it will become increasingly important to develop minimally invasive biomarkers.
This Research Topic will focus on recent advancements in the treatment of PCNSL with the aim of improving the prognosis for patients. We welcome submissions focusing on, but not limited to, the following topics:
- Novel targeted agents for the treatment of PCNSL
- Immunomodulatory drugs for the treatment of PCNSL
- Combination therapies for the treatment of PCNSL
- Overcoming the BBB in the treatment of PCNSL
- Overcoming drug resistance in PCNSL
- Validated biomarkers for treatment response in PCNSL
Please note: manuscripts that are solely based on bioinformatics or computational analysis of public databases without validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
